Related Experiment Video
Updated: Oct 26, 2025

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome
Oxana Megherea1, Carmen Janes2, Andrew Kowalski3
1Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
Ivosidenib and enasidenib are targeted agents that inhibit mutant isocitrate dehydrogenase (IDH) enzymes, restoring normal cellular differentiation in affected acute myeloid leukemia patients. Both agents carry a risk of differentiation syndrome (DS), a potentially life-threatening complication. In this multicenter, retrospective study we sought to determine the real-world incidence and characterize DS in patients with a myeloid malignancy treated with an IDH inhibitor. Of 49 total patients, 15 patients (31%) had a documented diagnosis of DS and 8 patients (16%) met the criteria of DS by Montesinos, et al. The most common signs and symptoms of DS were dyspnea/hypoxia (56%), unexplained fever (56%), bone pain/arthralgia (44%), edema/weight gain (39%), and pleural/pericardial effusions (33%). Our study reports a higher real-world incidence of DS in patients treated with IDH inhibitors for myeloid malignancies than previously reported.
Insights
Differentiation syndrome (DS) is a serious complication of IDH inhibitors used for acute myeloid leukemia. This study found a higher real-world incidence of DS in patients treated with these targeted agents.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Ivosidenib and enasidenib target mutant isocitrate dehydrogenase (IDH) enzymes.
- These agents are used to restore normal cellular differentiation in acute myeloid leukemia (AML).
- Differentiation syndrome (DS) is a known, potentially life-threatening complication associated with IDH inhibitors.
Purpose of the Study:
- To determine the real-world incidence of differentiation syndrome (DS).
- To characterize the clinical presentation of DS.
- In patients with myeloid malignancies treated with IDH inhibitors.
Main Methods:
- Multicenter, retrospective study design.
- Analysis of 49 patients with myeloid malignancies treated with IDH inhibitors.
- Evaluation for documented diagnosis and Montesinos criteria for DS.
Main Results:
- 15 patients (31%) had a documented diagnosis of DS.
- 8 patients (16%) met the Montesinos criteria for DS.
- Common DS symptoms included dyspnea/hypoxia (56%), fever (56%), bone pain (44%), edema (39%), and effusions (33%).
Conclusions:
- The real-world incidence of DS in patients treated with IDH inhibitors for myeloid malignancies appears higher than previously reported.
- Understanding the incidence and characteristics of DS is crucial for managing patients on IDH inhibitors.
- This study highlights the importance of monitoring for DS in this patient population.
More Related Videos
06:21Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model
Published on: May 27, 2016
08:36Metabolic Mapping: Quantitative Enzyme Cytochemistry and Histochemistry to Determine the Activity of Dehydrogenases in Cells and Tissues
Published on: May 26, 2018
Related Concept Videos
Assessment of Diffusion and Perfusion
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
iPS Cell Differentiation
Myocarditis II: Clinical Features and Diagnostic Tests
Intellectual Disability
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History